SPERO THERAPEUTICS INC's ticker is SPRO and the CUSIP is 84833T103. A total of 80 filers reported holding SPERO THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 2.52 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $121,000 | -51.4% | 13,885 | -10.7% | 0.00% | – |
Q4 2021 | $249,000 | -8.5% | 15,543 | +5.3% | 0.00% | – |
Q3 2021 | $272,000 | +27.7% | 14,763 | -3.0% | 0.00% | – |
Q2 2021 | $213,000 | +3.9% | 15,215 | +9.0% | 0.00% | – |
Q1 2021 | $205,000 | -30.3% | 13,953 | -8.2% | 0.00% | – |
Q4 2020 | $294,000 | +219.6% | 15,192 | +83.6% | 0.00% | – |
Q3 2020 | $92,000 | -9.8% | 8,276 | +10.0% | 0.00% | – |
Q2 2020 | $102,000 | +264.3% | 7,524 | +116.9% | 0.00% | – |
Q1 2020 | $28,000 | -63.2% | 3,469 | -56.3% | 0.00% | – |
Q4 2019 | $76,000 | +153.3% | 7,930 | +174.9% | 0.00% | – |
Q3 2019 | $30,000 | -65.9% | 2,885 | -62.7% | 0.00% | – |
Q2 2019 | $88,000 | -30.7% | 7,737 | -22.3% | 0.00% | – |
Q1 2019 | $127,000 | +89.6% | 9,954 | -9.8% | 0.00% | – |
Q4 2018 | $67,000 | -82.5% | 11,031 | -69.7% | 0.00% | – |
Q3 2018 | $382,000 | +13.0% | 36,408 | +57.4% | 0.00% | – |
Q2 2018 | $338,000 | +207.3% | 23,124 | +195.4% | 0.00% | – |
Q1 2018 | $110,000 | -29.0% | 7,827 | -41.1% | 0.00% | – |
Q4 2017 | $155,000 | – | 13,293 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Atlas Venture Associates IX, LLC | 1,353,303 | $1,637,497 | 13.93% |
Anson Funds Management LP | 4,159,572 | $5,033,082 | 1.01% |
OUP Management Co., LLC | 249,070 | $301,375 | 0.68% |
Atlas Venture Life Science Advisors, LLC | 1,013,438 | $1,226,260 | 0.19% |
Murchinson Ltd. | 862,700 | $1,043,867 | 0.13% |
Alphabet Inc. | 889,979 | $1,076,874 | 0.07% |
AWM Investment Company, Inc. | 333,400 | $403,414 | 0.06% |
DAFNA Capital Management LLC | 125,000 | $151,250 | 0.05% |
Novo Holdings A/S | 468,902 | $567,371 | 0.04% |
XTX Topco Ltd | 58,368 | $70,625 | 0.01% |